BKEMV
RegisteredWord Mark
•
Ownership
AI
Owner Name
Type: Organization / Corporation
Address
One Amgen Center Drive
Thousand Oaks, CA 913201799
Critical Dates
First Use Date
Apr 2, 2025
Filing Date
Jan 26, 2022
Registration Date
Jul 15, 2025
Mark Descriptions
Goods
Class 5
pharmaceutical preparations and substances for use in the treatment of hematological, autoimmune, blood cell and blood vessel diseases and disorders
Mark Elements
Text Mark
BKEMV
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO websiteTrademark Timeline
First Use
Filing Date
Publication Date
Registration Date
USPTO Records
| Title | Date | Category | Source | Pages | Format | Actions |
|---|---|---|---|---|---|---|
AI AssessmentCached Mar 12, 2026, 07:34 AMCached
AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.
Trademark Summary
The standard character mark BKEMV covers pharmaceutical preparations and substances for use in the treatment of hematological, autoimmune, blood cell and blood vessel diseases and disorders in International Class 005. It is owned by Amgen Inc., a Delaware corporation headquartered in Thousand Oaks, California. The mark is registered on the Principal Register with registration number 7868370, effective July 15, 2025, following conversion from an intent-to-use basis with first use in commerce on April 2, 2025. No active oppositions or legal proceedings are present.
Recent Activity
Filed on January 26, 2022, the application was published for opposition on May 24, 2022, and issued a notice of allowance requiring a statement of use. After five extensions, Amgen filed its statement of use on April 29, 2025, which was accepted, leading to registration on July 15, 2025.
USPTO
AI Analysis
v2.8.0
Never miss important updates for this trademark
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach